For all their speedy sequencing of genomes, scientists have yet to figure out what all the DNA data mean about diseases, holding back the information from being used in patient treatment.
As genomic data swells beyond expectations, researchers face a dilemma over how to secure the information on people's DNA without stymying progress in the genomics revolution. In an opinion column in Nature , University of California, Berkeley Professor Steven Brenner tackles the issue and lays out a set of potential solutions.
Nearly 70 organizations have united to form an ambitious global alliance to improve how genomic and clinical data are managed and shared.
Cambridge, MA-based software company GenoSpace has teamed up with a growing number of pharma, academic and tech groups to support tranSMART, a platform for improving the use of mass quantities of translational research data.
The FDA wants to infuse more data analytics into the agency's hunts for unlawful activity in the pharma industry. The regulator has put out a call for external experts to provide its investigators with access to real-time data on pharma product distribution and promotions, Regulatory Focus reports.
The company has raised 1.2 million euros ($1.5 million) to advance its genomics platform, attracting investments from the online payment group Ogone and Foundation Life Sciences Partners, BioInform reported.
Belgian biopharma group UCB has partnered with IBM to provide physicians with a predictive tool for use in treating epileptic patients, and the company has worked on expanding its offerings after patents expired on its epilepsy drug Keppra.
Oxford University is marshaling money and scientists to explore massive datasets to uncover knowledge about diseases and treatments.
GlaxoSmithKline has been listening to parents' concerns about childhood vaccinations. Really listening. In fact, it has used big data analytics to sift through thousands of comments from Internet chat forums to try to get a better grasp of exactly what objections there are and how to best face them.
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.